|
| Our live webinar is only 2 days away! |
|
| Drug Discovery in the Age of Genomics |
|
| Thursday, July 18, 2019 |
| 1:00pm EDT |
|
 |
|
| Currently, only 10% of drug therapies actually reach patients because the genetic mechanisms of disease and their consequences for drug action are not well understood. This incomplete understanding can result in R&D failures in the lab, diminished likelihood of success in clinical trials, and/or inappropriate diagnosis and treatment of patients in the clinic. |
|
| With the advent of Next Generation Sequencing (NGS), pharma and biopharma companies can begin to understand the biological processes underlying disease and change this devastating statistic. |
|
| GENOMICS EMPOWERS PHARMA AND BIOPHARMA TO: |
|
| • |
Choose better starting points for therapies |
| • |
Reduce R&D costs by focusing on validated targets |
| • |
Increase the chance of FDA approval with genetic evidence support |
| • |
Increase success of clinical trials through optimized patient selection |
| • |
Decrease time to market |
|
|
| In this webinar, genomics experts Drs. Mark Kiel and Alex Joyner will describe the deep and invaluable connection between therapeutics development and genomics, and how to obtain and use NGS data to improve outcomes. The discussion will include a demonstration of Mastermind, the genomic database that was built to meet the growing need for understanding of the genomic landscape of a disease or pathway in drug discovery and clinical trial design. |
|
| Is your organization making full use of NGS technology & genomic data to power your drug discovery? |
|
| FIND OUT AS YOU LEARN: |
|
| • |
How genomics can be used to facilitate drug discovery, e.g. prioritizing variants from among patient cohorts |
| • |
How genomics can be used to improve outcomes for clinical trials, e.g. maximizing patient recruitment and ensuring optimal patient response |
| • |
How genomics helps to decrease time to market for therapies, e.g. expediting FDA approval with documented genetic evidence |
|
|
| Please join us! |
|
| Can't make it? Register and we will send you a link to the recording. |
|
|
|
| ABOUT THE SPEAKERS: |
|
 |
|
Mark Kiel, MD, PhD |
|
|
Mark completed his MD PhD and Molecular Genetic Pathology Fellowship at the University of Michigan, where his research focused on stem cell biology, genomic profiling of hematopoietic malignancies, and clinical bioinformatics. He is the founder and CSO of Genomenon, where he supervises the scientific direction of the Mastermind suite of software tools.
|
|
|
 |
|
Alex Joyner, PhD |
|
|
Alex completed his PhD at the
University of California, San Diego in Biomedical Sciences with a focus on Bioinformatics, focusing on genomic profiling of autism patients and phenotypic association with brain imaging data. In industry, he has worked on optimization of variant calling algorithms and interpretation of NGS results in a clinical setting.
|
|
|
|
|
|
|
| Explore & Discover! |
| The Genomenon Team |
|
 |
|
| Connect With Us |
|
|
|
| hello@genomenon.com |
| 1-734-794-3075 |
|
